{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:20:15Z","timestamp":1791321615079,"version":"4.3.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,6,22]],"date-time":"2014-06-22T00:00:00Z","timestamp":1403395200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We investigated the long-term effects and safety of botulinum toxin-A (BTX-A) for treating trigeminal neuralgia (TN). We also studied long-term maintenance of this therapeutic effect.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A visual analog scale (VAS) score, pain attack frequency per day, patient\u2019s overall response to treatment and side effects during 14-month follow-up were evaluated in 88 patients with TN receiving BTX-A. The primary endpoints were pain severity (assessed by VAS) and pain attack frequency per day. The secondary endpoint was the patient\u2019s overall response to treatment, assessed using the Patient Global Impression of Change. The influence of different doses (\u226450, 50\u2013100 and \u2265100 U) on the therapeutic effect was evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Treatment was deemed \u201ceffective\u201d within 1\u00a0month in 81 patients and at 2\u00a0months in 88 patients (100%). The shortest period of effective treatment was 3\u00a0months, and complete control of pain was observed in a maximum of 46 patients. The therapeutic effect decreased gradually after 3\u00a0months, and the prevalence of effective treatment at 14\u00a0months was 38.6%, with complete control of pain seen in 22 patients (25%). There was no significant difference in the prevalence of effective treatment between different dose groups at identical time points (p\u2009&gt;\u20090.05). Three patients showed swelling at injection sites and 10 patients showed facial asymmetry, both of which disappeared spontaneously without special treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Local subcutaneous injection of BTX-A for TN treatment has considerable therapeutic effects lasting several months and is safe for this indication. At least one-quarter of patients maintained complete analgesia. The maintenance period of the therapeutic effect may be related to the reduction in the VAS score after the first injection of BTX-A.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1129-2377-15-43","type":"journal-article","created":{"date-parts":[[2014,6,22]],"date-time":"2014-06-22T07:01:36Z","timestamp":1403420496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Therapeutic effect of Botulinum toxin-A in 88 patients with Trigeminal Neuralgia with 14-month follow-up"],"prefix":"10.1186","volume":"15","author":[{"given":"Shuang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Jun","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Qing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Hong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Chang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ke","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,22]]},"reference":[{"issue":"1-2","key":"626_CR1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.pain.2006.01.030","volume":"122","author":"GC Hall","year":"2006","unstructured":"Hall GC, Carroll D, Parry D, McQuay HJ: Epidemiology and treatment of neuropathic pain: the UK primary care perspective [J]. Pain 2006, 122(1\u20132):156\u2013162.","journal-title":"Pain"},{"issue":"2","key":"626_CR2","first-page":"440","volume":"44","author":"YJ Lian","year":"2009","unstructured":"Lian YJ, Wei HL, Zhang BA, Liu HB, Xu YM, Fang SY, Li ZF, Fang GY, Lu H, Jia YJ, Zhao XY, Wei JK, Zhang L, Song B: Treatment of 795 facial spasm and local dystonia with Botulinum toxin A. J Zhengzhou Univ (Med Sci) 2009, 44(2):440\u2013442.","journal-title":"J Zhengzhou Univ (Med Sci)"},{"key":"626_CR3","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1529\/biophysj.104.048637","volume":"87","author":"ME Bowen","year":"2004","unstructured":"Bowen ME, Weninger K, Bnmger AT: Single molecule observation of liposome-bilayer fusion thermally induced by soluble Nethyl maleimide sensitive factor attachment protein receptors (SNAREs). Biophys J 2004, 87: 3569\u20133584.","journal-title":"Biophys J"},{"key":"626_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/00002826-200209000-00006","volume":"25","author":"F Micheli","year":"2002","unstructured":"Micheli F, Scorticati MC, Raina G: Beneficial effects of botulinum toxin type A for patients with painful tic convulsif. Clin Neuropharmacol 2002, 25: 260\u2013262.","journal-title":"Clin Neuropharmacol"},{"key":"626_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/0333102412441721","volume":"32","author":"CJ Wu","year":"2012","unstructured":"Wu CJ, Lian YJ, Zheng YK: Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 2012, 32: 443\u2013450.","journal-title":"Cephalalgia"},{"issue":"5","key":"626_CR6","first-page":"483","volume":"26","author":"JH Shen","year":"2011","unstructured":"Shen JH, Lian YJ, Zheng YK, Xie YY, Wei HL: Treatment of primary trigeminal neuralgia with botulinum toxin type A. China J Rehabil Med 2011, 26(5):483\u2013484.","journal-title":"China J Rehabil Med"},{"key":"626_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tripleo.2010.04.043","volume":"111","author":"B Bohluli","year":"2011","unstructured":"Bohluli B, Motamedi MH, Bagheri SC, Bayat M, Lassemi E, Navi F, Moharamnejad N: Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011, 111: 47\u201350.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"1","key":"626_CR8","first-page":"32","volume":"19","author":"TG Zhu","year":"2011","unstructured":"Zhu TG, Zhang QL, Luo WF, Mao CJ, Hu WD, Liu CF: Clinical treatment of refractory trigeminal neuralgia with botulinum toxin type A. China Clinical Neuroscience 2011, 19(1):32\u201335.","journal-title":"China Clinical Neuroscience"},{"key":"626_CR9","volume-title":"Clin J Pain","author":"F Gustavo","year":"2013","unstructured":"Gustavo F, Jose DA, Villanueva P, Asensio-Samper JM: Subcutaneous and perineural Botulinum Toxin Type A For Neuropathic Pain. Clin J Pain 2013. [Epub ahead of print]"},{"key":"626_CR10","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1111\/j.1526-4637.2010.01003.x","volume":"11","author":"L Xiao","year":"2011","unstructured":"Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D: Subcutaneous injection of botulium toxin A is beneficial in postherpetic neuralgia. Pain Med 2011, 11: 1827\u20131833.","journal-title":"Pain Med"},{"key":"626_CR11","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1212\/01.wnl.0000345968.05959.cf","volume":"72","author":"RY Yuan","year":"2009","unstructured":"Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, Hu CJ: Botulinum toxin for diabetic neuropathic pain:a randomized double-blind crossover trial. Neurology 2009, 72: 1456\u20131478.","journal-title":"Neurology"},{"key":"626_CR12","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1111\/j.1526-4610.2008.01089.x","volume":"48","author":"M Taylor","year":"2008","unstructured":"Taylor M, Silva S, Cottrell C: Botulinum toxin type A in the treatment of occipital neuralgia: a pilot study. Headache 2008, 48: 1476\u20131481.","journal-title":"Headache"},{"issue":"15","key":"626_CR13","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1177\/0333102412459578","volume":"32","author":"CJ Wu","year":"2012","unstructured":"Wu CJ, Lian YJ: Botulium toxin type A for trigeminal neuralgia-we have the prima facie evidence. Cephalagia 2012, 32(15):1156\u20131157.","journal-title":"Cephalagia"},{"key":"626_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1054\/jpai.2002.27142","volume":"3","author":"GE Borodic","year":"2002","unstructured":"Borodic GE, Acquadro MA: The use of botulinum toxin for the treatment of chronic facial pain. J Pain J Pain 2002, 3: 21\u201327.","journal-title":"J Pain J Pain"},{"key":"626_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.wnf.0000172497.24770.b0","volume":"28","author":"U Turk","year":"2005","unstructured":"Turk U, Ilhan S, Alp R, Sur H: Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005, 28: 161\u2013162.","journal-title":"Clin Neuropharmacol"},{"key":"626_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1590\/S0004-282X2008000400012","volume":"66","author":"C Zuniga","year":"2008","unstructured":"Zuniga C, Diaz S, Piedimonte F, Micheli F: Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr 2008, 66: 500\u2013503.","journal-title":"Arq Neuropsiquiatr"},{"key":"626_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"KR Aoki","year":"2005","unstructured":"Aoki KR: Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26: 785\u2013793.","journal-title":"Neurotoxicology"},{"key":"626_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pain.2008.10.005","volume":"141","author":"P Gazerani","year":"2009","unstructured":"Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L: Subcutaneous botulinum toxin type A reduces capsaicin-indecd trigeminal pain and vasomotor reactions in human skin. Pain 2009, 141: 60\u201369.","journal-title":"Pain"},{"key":"626_CR19","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1523\/JNEUROSCI.5490-08.2009","volume":"29","author":"J Meng","year":"2009","unstructured":"Meng J, Ovsepian SV, Wang J: Activation of TRPV1 mediates calcitonin generelated peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum boxin with anti-nociceptive potential. J Neurosci 2009, 29: 4981\u20134992.","journal-title":"J Neurosci"},{"key":"626_CR20","doi-asserted-by":"publisher","first-page":"7723","DOI":"10.1073\/pnas.96.14.7723","volume":"96","author":"CJ Woolf","year":"1999","unstructured":"Woolf CJ, Costigan M: Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci 1999, 96: 7723\u20137730.","journal-title":"Proc Natl Acad Sci"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1129-2377-15-43\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1129-2377-15-43.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1129-2377-15-43.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T04:34:39Z","timestamp":1630557279000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/1129-2377-15-43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,22]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1186\/1129-2377-15-43","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,22]]},"assertion":[{"value":"5 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"43"}}